Handelsbanken Fonder AB Makes New Investment in Structure Therapeutics Inc. (NASDAQ:GPCR)

Handelsbanken Fonder AB purchased a new position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 165,000 shares of the company’s stock, valued at approximately $4,475,000.

Several other hedge funds and other institutional investors have also made changes to their positions in GPCR. Point72 Asset Management L.P. raised its stake in Structure Therapeutics by 196.5% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,238,268 shares of the company’s stock valued at $54,348,000 after purchasing an additional 820,589 shares during the last quarter. Janus Henderson Group PLC grew its holdings in shares of Structure Therapeutics by 18.0% during the 3rd quarter. Janus Henderson Group PLC now owns 3,956,878 shares of the company’s stock worth $173,623,000 after purchasing an additional 602,609 shares during the period. Vestal Point Capital LP boosted its holdings in Structure Therapeutics by 105.4% in the 3rd quarter. Vestal Point Capital LP now owns 1,150,000 shares of the company’s stock worth $50,474,000 after acquiring an additional 590,000 shares during the period. FMR LLC boosted its holdings in Structure Therapeutics by 6.7% in the 3rd quarter. FMR LLC now owns 6,128,444 shares of the company’s stock worth $268,977,000 after acquiring an additional 383,635 shares during the period. Finally, Principal Financial Group Inc. raised its position in shares of Structure Therapeutics by 230.0% in the 3rd quarter. Principal Financial Group Inc. now owns 545,359 shares of the company’s stock valued at $23,936,000 after purchasing an additional 380,115 shares in the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Price Performance

GPCR opened at $23.70 on Monday. Structure Therapeutics Inc. has a fifty-two week low of $22.33 and a fifty-two week high of $62.74. The business has a 50-day moving average of $27.37 and a 200-day moving average of $34.02. The company has a market capitalization of $1.36 billion, a PE ratio of -32.02 and a beta of -2.75.

Analyst Ratings Changes

Several research firms recently issued reports on GPCR. JMP Securities reissued a “market outperform” rating and set a $91.00 price target on shares of Structure Therapeutics in a research report on Wednesday, December 18th. Stifel Nicolaus initiated coverage on Structure Therapeutics in a research note on Wednesday, January 8th. They issued a “buy” rating and a $50.00 price target for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $80.00 target price on shares of Structure Therapeutics in a research note on Thursday, December 19th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average target price of $81.29.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.